home.aspx
 
EVENTS

Internal Medicine for Primary Care
INTERNAL MEDICINE FOR PRIMARY CARE
October 30-01, 2020
The Internal Medicine for Primary Care conference will cover areas like Internal Medicine for Primary Care Physicians, Issues in Women's Health Cardio, Pulmonary for Primary Care Physicians, Neurology for the Non-Neurologist.

Symposium on Advanced Wound Care Fall
SYMPOSIUM ON ADVANCED WOUND CARE FALL
October 30-01, 2020
The Symposium on Advanced Wound Care Fall meeting (SAWC Fall) serves as a forum to connect the entire wound care team — physicians, nurses, physical therapists, researchers, scientists, podiatrists, and dietitians — with the foremost experts in wound care to improve patient outcomes thro...

Astra Nova Training

SHARESHARESHARE
Astra Nova Training is a UK-based training organization, which focuses on pharma and clinical research in-house training solutions through our international network of training professionals.
SHARESHARESHARE

RELATED NEWS


AstraZeneca has announced the US Food and Drug Administration (FDA) has approved Farxiga (dapagliflozin) to reduce the risk of hospitalisation for heart failure (hHF) in patients with type 2 diabetes and either established cardiovascular disease (CVD) or at serious risk of CV outcomes. This follows a similar decision by the European Union in August 2019, when the medicines agency updated its marketing authorisation for Farxiga. The FDA’s decision was based upon results from the DECLARE-TIM...

READ MORE

AstraZeneca has revised its agreement with Ironwood Pharmaceuticals for irritable bowel syndrome with constipation (IBS-C) drug Linzess (linaclotide). Linzess is a guanylate cyclase-C (GC-C) agonist, which activates the GC-C receptor, leading to improved secretion of intestinal fluid and transit and a decrease in the activity of intestine’s pain-sensing nerves. The drug received the Chinese National Medical Products Administration approval for adult patients in January. It is expected to b...

READ MORE

AstraZeneca already has a Tagrisso approval for patients with previously untreated, EGFR-mutated lung cancer. But its shoring up its case with some clutch new data. Friday, the British drugmaker said Tagrisso had beaten out Roches rival drug Tarceva and AstraZenecas own Iressa at helping patients live longer. The showing came as part of the phase 3 Flaura trial the same study that helped net Tagrisso its approval last year based on a reduction in the risk of disease progression. That overall sur...
FIERCE PHARMA
READ MORE

The U.S. FDA compiles a list of off-patent drugs without an approved generic to encourage the development of copycats. Now, the Chinese authorities are rolling out a similar initiative, only with some extra incentives. On Thursday, China’s National Health Commission published (Chinese) its first proposed list of 34 drugs (full list below) that the agency says are already off patent or nearing patent expiration but have no generic drug application in the country or lack competition. The pla...

READ MORE

AstraZeneca has taken a lot of heat for its massive new headquarters and R&D facility in Cambridge, U.K., which has been beset by everything from cost overruns to a four-year completion delay. So it’s no wonder the drugmaker buried the latest details about the project on page 27 of its 244-page annual report. AstraZeneca originally planned to spend £330 million on the new building and to start shifting employees there in 2016. Now, the cost has zoomed to £750 million, which...

READ MORE

AstraZeneca’s Novel START trial for its Symbicort Turbuhaler (budesonide/formoterol) demonstrated a reduction in the rate of asthma attacks in patients with mild asthma, compared to common therapies. The trial results, published in the ‘New England Journal of Medicine’, compared Symbicort Turbuhaler with two commonly used treatment regimens in mild asthma and reflected real-world practice. In real-world practice, patients typically use a short-acting beta2-agonist (SABA) reliev...

READ MORE

AstraZeneca has announced top-line results from the pooled cardiovascular (CV) safety analyses of its global Phase III roxadustat programme. One of the key CV safety endpoints is major adverse CV events (defined as MACE), and another key CV safety endpoint evaluated MACE plus heart failure requiring hospitalisation and unstable angina requiring hospitalisation (defined as MACE+). The first-in-class hypoxia-inducible-factor prolyl hydroxylase inhibitor (HIF-PHI) was evaluated in three separate te...

READ MORE

AstraZeneca and Forty Seven are evaluating a new triple combination therapy clinical trial that has the potential to create additional opportunities to further optimise treatment for patients with diffuse large B-cell lymphoma. Forty Seven’s CD47 antibody, ‘5F9’, will be tested in combination with rituximab and Calquence (acalabrutinib) for the aggressive form of non-Hodgkin’s lymphoma (NHL). The study aims to build upon the promising results already reported from a Phase...

READ MORE

AstraZeneca has announced that pooled analyses of the phase III trials for its kidney disease drug roxadustat confirm the drug’s cardiovascular safety – a good sign for the potential blockbuster that hopes to compete with well-established treatments. Roxadustat, co-developed with FibroGen and Astellas, is a first-in-class HIF-PHI inhibitor for the treatment of anaemia caused by chronic kidney disease (CKD), which affects more than 200 million people worldwide. It is looking to take o...

READ MORE

AstraZeneca’s Fasenra is already pressuring GlaxoSmithKline's Nucala in severe eosinophilic asthma, and new data could help set up a showdown between the two in another indication. By week 12 of a phase 2 study in hypereosinophilic syndrome (HES), Fasenra cut patients' blood eosinophil counts by at least half, AstraZeneca showed with results published Thursday. Only 30% of patients taking placebo reached that mark. In patients with biopsies taken, results showed a “near-compl...
FIERCEPHARMA
READ MORE

EVENTS

Vital Signs EMS Conference
VITAL SIGNS EMS CONFERENCE
October 29-01, 2020
Vital Signs EMS Conference will be showcasing many of the extraordinary aspects of EMS and healthcare found only in Saratoga Springs. This event provided high quality and cutting edge EMS education by providing access to national and world-renowned educators through a forum that is accessible and af...

Update CME - Internal Medicine & Primary Care
UPDATE CME - INTERNAL MEDICINE & PRIMARY CARE
October 29-01, 2020
Earn 30 CME Credits by attending our Update CME Internal Medicine and Primary Care Conference either in person or via live stream!Expert speakers from The University of Chicago, Johns Hopkins, and University of California, Los Angeles will be presenting on the latest clinical guidelines. We offer in...